To enhance the potential of LCM and to overcome some of the limitations of other methods, we have developed a rapid, simple procedure for enrichment of normal and tumor cells called epithelial ...

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.